Recommendations within the International Adaptations are represented as follows:
Prostate Cancer Version 4.2024 (English)
Cervical Cancer Version 1.2023 (English)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 2.2023 (English)
Uterine Neoplasms Version 2.2023 (English)
Adult Cancer Pain Version 2.2022 (English)
Breast Cancer Version 2.2023 (English)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 2.2023 (English)
Colon Cancer Version 2.2022 (English)
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 2.2022 (English)
Hairy Cell Leukemia Version 1.2023 (English)
Hepatobiliary Cancers Version 2.2022 (English)
Hodgkin Lymphoma Version 2.2022 (English)
Non-Small Cell Lung Cancer Version 3.2022 (English)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 1.2022 (English)
Prostate Cancer Version 4.2022 (English)
T-Cell Lymphomas Version 2.2022 (English)
Breast Cancer Version 4.2023 (English)
Central Nervous System Cancers Version 2.2021 (English)
Cervical Cancer Version 1.2021 (English)
Colon Cancer Version 2.2022 (English)
Head and Neck Cancers Version 2.2022 (English)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 5.2022 (English)
Squamous Cell Skin Cancer Version 2.2020 (English)